Dr. Leonardo Ferreira, an assistant professor of microbiology and immunology at the Medical University of South Carolina and the Hollings Cancer Center, has joined us for this week''s episode of Teach Me in 10.
T1D is the most common form of diabetes in infants and adolescents, because when the immune system targets the patients own insulin-producing pancreatic islet cells for destruction. Yet, this technique requires life-long immunosuppression to prevent immune rejection and autoimmunity. Ferreira is looking at the use of regulatory T cells as living medications to treat T1D.
This approach, which is unique because it involves the root cause of the disease, and the immune attack of pancreatic islets by genetically engineering human regulatory T cells to induce tolerance to pancreatic islets. He believes this line of work will assist realize the promise of T1D immune therapy, and how it can be accomplished in less than ten minutes.
Ferreira advises for further reading:
- Next-generation regulatory T cell therapy
- Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance
- Modeling human T1D-associated autoimmune processes
In ten videos, you can check out our LabTube channel.